PSMA diagnostics and therapy

Prostate cancer is now the most commonly diagnosed non-cutaneous malignancy in the UK, accounting for over 40,000 new diagnoses and 11,000 deaths annually. It is estimated that more than 400,000 men are currently living with the disease. Recent years have seen massive improvements in the understanding and treatment of prostate cancer, in particular the treatment of the potentially lethal variety. Despite these advances, there remain considerable unmet needs in the diagnosis and management of this heterogenous disease. Exploitation of a protein on the surface of prostate cancer cells first described in 1990, prostate-specific membrane antigen (PSMA), may lead to significant improvements in the detection and treatment of prostate cancer. There is now a considerable amount of data supporting the use of PSMA as both a molecular imaging and a therapeutic target. This article will briefly describe the current state-of-the-art knowledge on PSMA PET imaging and also present some very recent phase 3 trial data on radioligand PSMA-targeted therapy using Lu-177 PSMA-617.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.